BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MD Buyline's User Satisfaction Report Awards MGC Diagnostics Corporation Pulmonary Function Products Top Rating for Fourth Consecutive Quarter


3/4/2013 10:54:29 AM

SAINT PAUL, Minn., March 4, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today announced that its pulmonary function products, service and support continues to outperform industry competitors as well as increasing its margin above Market Average. As published in MD Buyline's User Satisfaction Report, MGC Diagnostics has earned the top rating in all categories for its fourth consecutive quarter. Ratings based on user satisfaction ranks MGC Diagnostics system performance, system reliability, installation/implementation, applications training, service response time and service repair quality singularly higher compared to other vendors in this space.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

Gregg O. Lehman, Ph.D., Chief Executive Officer and President of MGC Diagnostics, commented, "We are pleased to be recognized by our customers in the report from MD Buyline for consistently providing unmatched service and support, relentlessly making improvements and anticipating and solving unmet needs. These core commitments guide our strategy and define our commitment to customers, employees and shareholders making us uniquely qualified to solve today's challenges and uncover solutions for tomorrow's opportunities."

About MD Buyline MD Buyline, the leading provider of healthcare technology and clinical research for reducing the purchasing costs across the healthcare supply chain, provides over 3,000 healthcare providers with unbiased, up-to-the-minute data on vendors, products, services, and user satisfaction ratings to ensure they invest in the right technology and services at the right price. www.mdbuyline.com

About MGC Diagnostics

MGC Diagnostics Corporation, (formerly Angeion Corporation) through its subsidiary Medical Graphics Corporation, is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements

From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forwardlooking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forwardlooking statements, the Company claims the protection of the safe harbor for forwardlooking statements contained in federal securities laws. These forwardlooking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forwardlooking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

Contact:

Gregg O. Lehman, Ph.D.

Joe Dorame, Robert Blum, Joe Diaz


MGC Diagnostics Corporation

Lytham Partners, LLC


Chief Executive Officer

(602) 889-9700


(651) 484-4874

mgcd@lythampartners.com

SOURCE MGC Diagnostics Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES